Kv1.3 细胞系

Aurora Biomed Inc. offers cell lines for purchasing and licensing for some of the most common drug discovery ion channel targets. Our cell line collection includes the hERG and Kv1.3 potassium channels, and the Nav1.5 sodium channel. Each cell line has been optimized by our assay development team to stably express the ion channel of interest, and has been validated using both flux assays and electrophysiology. The window of detection (signal/noise) of these cell lines is appropriate for high-throughput screens.

These cell lines, when used with Aurora Biomed’s Ion Channel Reader Series and optimized reagents, can help generate robust, sensitive assays for ion channel screening.

The Kv1.3 potassium channel has shown promise as a pharmaceutical target for such diseases as multiple sclerosis, obesity, and more recently, diabetes. In order to screen large compound libraries against Kv1.3, a reliable expression system is needed.

Our CHO-Kv1.3 potassium channel cell line was specifically designed to express high levels of Kv1.3 channels, and to show uniform expression over time.

• Stably expresses Kv1.3 potassium channels
• Validated using electrophysiology and efflux assay
• Suitable for high-throughput screening (HTS)

资源下载

High-Throughput Screening for Kv1.3 Channel Blockers Using an Improved FLIPR-Based Membrane-Potential Assay

资料下载：Kv1.3 细胞系